Price
993.6
+0.54%52W Range
Market Cap
₹2,050.42 Cr
Traded: ₹17.03 Cr (0.83%) 0.0x
Free Float: ₹501.94 Cr (3.39% of FF traded)
Volume · 60D trend
1.73 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | +16.0% | +21.0% | -- | +19.0% | Stable |
| Profit | -- | +16.0% | +17.0% | -- | +9.0% | Stable |
| Return | -- | -- | +42.0% | -18.0% | -- | Decelerating |
| ROE | -- | +12.0% | +13.0% | -- | -- | Accelerating |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 238 | 233 | 222 | 210 | 203 | 195 | 187 | 175 | 171 | 162 | 153 | 145 | 141 | 120 | 133 |
| Expenses | 213 | 209 | 194 | 184 | 177 | 170 | 164 | 154 | 149 | 142 | 134 | 128 | 124 | 106 | 117 |
| Operating Profit | 25 | 24 | 29 | 27 | 26 | 25 | 23 | 21 | 22 | 20 | 19 | 17 | 16 | 14 | 16 |
| OPM % | 11.0% | 10.0% | 13.0% | 13.0% | 13.0% | 13.0% | 12.0% | 12.0% | 13.0% | 13.0% | 12.0% | 12.0% | 12.0% | 12.0% | 12.0% |
| Other Income | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 2 | 2 | 3 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 8 | 8 | 8 | 7 | 8 | 7 | 6 | 6 | 4 | 3 | 3 | 3 | 4 | 3 | 3 |
| Profit Before Tax | 20 | 20 | 24 | 23 | 21 | 20 | 20 | 18 | 23 | 20 | 18 | 16 | 15 | 13 | 16 |
| Tax % | 21.0% | 25.0% | 25.0% | 24.0% | 22.0% | 23.0% | 23.0% | 26.0% | 25.0% | 24.0% | 23.0% | 26.0% | 24.0% | 28.0% | 22.0% |
| Net Profit | 16 | 15 | 18 | 18 | 16 | 16 | 16 | 13 | 17 | 15 | 14 | 12 | 11 | 9 | 12 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 7.6 | 7.1 | 8.4 | 8.4 | 7.8 | 7.5 | 7.5 | 6.5 | 8.2 | 7.3 | 6.8 | 5.8 | 5.4 | 4.3 | 5.6 |
| Sales Growth (YoY) | 17.7% | 19.5% | 18.9% | 19.9% | 18.3% | 20.2% | 22.5% | 21.0% | 21.7% | 35.5% | 15.0% | 20.7% | 15.2% | -- | -- |
| Sales Growth (QoQ) | 2.1% | 5.0% | 5.7% | 3.5% | 4.1% | 4.3% | 6.9% | 2.3% | 5.6% | 5.9% | 5.5% | 2.8% | 17.5% | -9.8% | -- |
| OP Growth (YoY) | -3.8% | -4.0% | 26.1% | 28.6% | 18.2% | 25.0% | 21.1% | 23.5% | 37.5% | 42.9% | 18.8% | -- | -- | -- | -- |
| OP Growth (QoQ) | 4.2% | -17.2% | 7.4% | 3.8% | 4.0% | 8.7% | 9.5% | -4.5% | 10.0% | 5.3% | 11.8% | 6.3% | 14.3% | -12.5% | -- |
| Profit Growth (YoY) | -1.8% | -3.7% | 13.7% | 31.0% | -4.2% | 3.2% | 11.6% | 11.7% | 48.5% | 64.3% | 15.1% | 23.2% | -22.6% | 10.6% | 46.9% |
| EPS Growth (YoY) | -2.5% | -4.4% | 12.8% | 30.7% | -4.9% | 2.6% | 11.0% | 11.2% | 51.9% | 70.4% | 20.8% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 6.5% | -15.7% | 0.2% | 8.5% | 4.3% | -0.5% | 16.1% | -21.1% | 12.5% | 7.6% | 16.4% | 7.8% | 26.3% | -23.8% | -- |
| OP Margin | 10.5% | 10.3% | 13.1% | 12.9% | 12.8% | 12.8% | 12.3% | 12.0% | 12.9% | 12.3% | 12.4% | 11.7% | 11.3% | 11.7% | 12.0% |
| Net Margin | 6.7% | 6.4% | 8.1% | 8.6% | 7.9% | 8.2% | 8.6% | 7.4% | 9.9% | 9.3% | 9.2% | 8.3% | 7.8% | 7.5% | 9.0% |
| Material Cost % | 62.0% | 62.0% | 62.0% | 62.0% | 62.0% | 62.0% | 62.0% | 62.0% | 63.0% | 63.0% | 63.0% | 63.0% | 63.0% | 63.0% | 64.0% |
| Employee Cost % | 17.0% | 18.0% | 16.0% | 15.0% | 16.0% | 16.0% | 17.0% | 16.0% | 13.0% | 14.0% | 14.0% | 14.0% | 13.0% | 15.0% | 13.0% |
| P/S | 2.27 | 1.94 | 1.92 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 31.46 | 25.12 | 23.52 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 3.53 | 3.15 | 2.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Q1 FY27 Earnings Conference Call Transcript enclosed.
Audio Recording Q1 conference call
approval of the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.
approval of the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.
Investor Presentation - Q1 FY27 enclosed
Press release titled 'Windlas Biotech Limited Reports its Q1 FY27 Financial Results'
Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Notice is hereby given that ....
Submission of Combined Voting Results and Scrutinizer's Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') ....
Submission of Combined Voting Results and Scrutinizer's Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') ....
Proceedings of 25th Annual General Meeting of the Company held on July 23, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Certificate under Regulation 74 (5) of the SEBl (Depositories and Participants) Regulations, 2018 for the Quarter ended June 30, 2026
Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
Newspaper Advertisement of completion of despatch of the Notice of 25th Annual General Meeting and Annual Report for the financial year 2025-2026
Notice of 25th AGM
Intimation of cut-off date for evoting and dividend
Notice of 25th AGM to be held on July 23, 2026
Annual Report for FY26
Intimation of record date/ cut-off date for the 25th AGM and evoting
Newspaper Advertisement of 25th Annual General Meeting
Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015- Credit Rating
Intimation of Schedule of Analyst/Institutional Investor Meetings
Intimation of Closure of Trading Window
Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
Q4 & FY26 Earnings Conference Call Transcript
Annual Secretarial Compliance Report for the financial year ended March 31, 2026
Audio recording of Investors/ Analyst conference call on the audited consolidated and standalone financial results of the Company for the quarter and financial year ended March 31, 2026,.
Approval of audited consolidated and standalone financial results and recommendation of dividend
Approval of audited consolidated and standalone financial results for the year ended March 31, 2026 along with recommendation of final dividend
Investor Presentation - Q4 & FY26
'Windlas Biotech Limited Reports its Q4 and FY26 Financial Results'
Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 regarding grant of Stock Options/ Units under 'WBL Employee Stock Option ....
Completion of Extinguishment of 4,70,000 fully paid-up equity shares of face value of INR 5 each pursuant to buyback of Windlas Biotech Limited (the 'Company') in accordance with Regulation ....
Schedule of Conference Call to discuss financial performance for quarter and financial year ended March 31, 2026
Update regarding Labour Protest in Dehradun
Post Buyback Public Advertisement pursuant to and in compliance with Buyback Regulations. The Post Buyback Public Advertisement dated May 15, 2026 has been published in the newspapers on ....
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund
Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve the audited standalone and ....
Appointment of Dr. Tarashree Singhal as Independent Woman Director and cessation of directorship of Mr. Srinivasan Venkataraman.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Submission of newspaper publications regarding dispatch of Letter of Offer of Buyback to the shareholders of the Company
Buyback of 4,70,000 (Four Lakh Seventy Thousand) fully paid-up Equity Shares of the face value of INR 5 each ('Equity Shares') of Windlas Biotech Limited (the 'Company') at a price of INR ....
Submission of Public Announcement pertaining to Buyback of shares of the Company published in newspapers and Board Resolution
Regulation 30 and Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR Regulation') as amended
Regulation 30 and Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR Regulation') as amended for ....
Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/04/2026 ,inter alia, to consider and approve agenda is the proposal to buyback ....
Certificate under Regulation 74 (5) of the SEBl (Depositories and Participants) Regulations, 2018 for the Quarter ended March 31, 2026
Intimation of Closure of Trading Window
Result of Postal Ballot
Credit Ratings
6Concalls
20Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Sep 2021
30 Sept 2021Sep 2021
30 Sept 2021Held by ETFs
1 ETFs hold WINDLAS · sorted by weight
Held by Mutual Funds
4 schemes hold WINDLAS · sorted by weight